TcL Pharma appoints board member and operations director

French biotech develops antibodies to treat auto-immune diseases

TcL Pharma, a French biotech company dedicated to the development of antibodies for the treatment of auto-immune diseases has appointed Didier Hoch to its board of directors and Jean-Hugues Masgnaux as operations director.

Hoch has 25 years’ experience in the pharmaceutical industry and in vaccines. Between 2000 and 2010 he ran Sanofi Pasteur MSD, where he led the launch of Gardasil. Prior to this, he carried out various management functions at Rhône Poulenc Rorer (1985-2000), then joined Aventis (Europe, Middle-East/African regions) from 2000 to 2010. He is also a past president (2003-2009) of the European Vaccines Manufacturers Association EVM, and since 2006 has presided over the French Pharmaceutical Companies Association LEEM.

Masgnaux began his career as a consultant at Innothera Laboratories & CNI, going on to become manager of Licences & Agreements at Servier Group and product manager for Fournier Group. Between 1996 and 2000 he progressed from senior product manager to regional sales director and then marketing manager at Bayer Pharma. Between 2000 and 2005 he was Infectiology marketing manager for the France subsidiary of the Gruenenthal group, then international project manager and marketing director. In 2005 he took on the role of president of Madaus Laboratories France, becoming president of the Rottapharm/Madaus Group. In July 2009, he set up M&M Conseil and among other activities works as a health expert for Capgemini Consulting.

You may also like

Finance

Merck to acquire cancer biotech Terns Pharmaceuticals for $6.7bn

The purchase is the third multibillion-dollar acquisition for the pharma giant in the past year, as it moves to bolster its cancer portfolio ahead of its best-selling drug Keytruda losing patent protection in 2028
Marketing

Indena to highlight expanded HPAPI, ADC and peptide drug conjugate capabilities at DCAT Week 2026

Italian CDMO Indena will showcase its high-potency API manufacturing expertise and growing oncology-focused capabilities at DCAT Week in New York, including ten commercial HPAPIs in production and advancing work in antibody-drug and peptide drug conjugates
Manufacturing

Wilmington PharmaTech invests $50m into US small-molecule API manufacturing plant

The CRDMO will more than double the capacity in its current API reactor in Delaware, positioning itself to meet growing demand for US-based manufacturing
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

The challenges of developing combination products

Regulatory complexity and the case for a holistic development strategy
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Manufacturing

Clariant opens first US pharmaceutical-grade PEG excipient manufacturing site in Texas

Clariant has expanded its Clear Lake facility in Texas to produce GMP-compliant pharmaceutical-grade polyethylene glycol excipients, marking its first US-based manufacturing site for the products and strengthening supply chain resilience for North American and Latin American pharma customers
Subscribe now